论文部分内容阅读
目的 探讨骨化三醇联合骨肽注射液对老年男性骨质疏松症患者骨密度、血清胰岛素样生长因子及骨碱性磷酸酶表达的影响.方法 将120例老年男性骨质疏松症患者按照随机数字表法分为两组,各60例.两组均给予骨化三醇治疗,实验组联合骨肽注射液治疗,观察6个月.比较两组临床疗效,治疗前后两组骨密度值、血清胰岛素样生长因子及骨碱性磷酸酶表达水平变化情况,比较两组不良反应发生情况.结果 实验组总有效率为93.3％,对照组为80.0％,实验组显著高于对照组(P＜0.05).治疗后对照组腰椎骨密度值显著高于治疗前(P＜0.01),实验组腰椎及髋部骨密度值均显著高于治疗前(P＜0.01),且较对照组升高更显著(P＜0.05).治疗后对照组血清骨碱性磷酸酶水平显著高于治疗前(P＜0.01),实验组血清胰岛素样生长因子及骨碱性磷酸酶水平均显著高于治疗前(P＜0.01),且较对照组升高更显著(P＜0.05或0.01).两组不良反应发生率比较差异无统计学意义(P＞0.05).结论 骨化三醇联合骨肽注射液治疗老年男性骨质疏松症患者疗效显著,可显著提高患者的骨密度值、血清胰岛素样生长因子及骨碱性磷酸酶水平,安全性高.“,”Objective To explore the effect of calcitriol combined with ossotide injection on bone density, serum IGF-I and BAP in elderly male patients with osteoporosis. Methods 120 elderly patients with osteoporosis were divided into two groups according to the random number table, 60 cases in each group. The two groups were all given calcitriol treatment, and the experimental group was given calcitriol combined with ossotide injection, patients were observed for 6 months. The therapeutic effects, the BMD, serum IGF-I,BAP level changes, and the adverse reactions of the two groups were compared. Results The total effective rate of the experimental group was 93.33％, higher than that of the control group (80％) (P＜0.05). After treatment, the bone mineral density of lumbar and hip in the control group was significantly higher than that before treatment (P＜0.01),the bone mineral density of lumbar and hip in the experimental group was significantly higher than that before treatment (P＜0.01), and increased more significantly than that in the control group (P＜0.05). After treatment, serum BAP level in the control group was significantly higher than that before treatment (P＜0.01),serum IGF-I,BAP levels in the experimental group were significantly higher than those before treatment (P＜0.01),and increased more significantly than those in the control group (P＜0.05 or P＜0.01). There was insignificant difference in the adverse reaction between the two groups (P＞0.05). Conclusion Calcitriol combined with ossotide injection on treating elderly male patients with osteoporosis can significantly increase the bone mineral density value, serum IGF-I,BAP levels, and have high safety.